Panacea Biotec Share Price

In the past two months, the stock price of Panacea Biotec has skyrocketed 101 per cent.

• Business Standard
• 3 days 5 hours ago

Biotechnology company Panacea Biotec announced Q4FY26 & FY26 results Consolidated Financial Results: Consolidated Revenue from Operations for Q4FY26 stood at Rs 16,675 lakh, compared to Rs 16,519 lakh in Q3FY26, representing a QoQ increase of 0.94%, and a YoY increase of 25.82% from Rs 13,253 lakh in Q4FY25. Consolidated Total Income for Q4FY26 was Rs 16,930 lakh, showing a QoQ growth of 1.09% from Rs 16,747 lakh and a YoY growth of 19.97% from Rs 14,112 lakh in Q4FY25. The company reported a Consolidated Net Loss of Rs 100 lakh for Q4FY26, compared to a Net Profit of Rs 389 lakh in Q3FY26 and a Net Loss of Rs 199 lakh in Q4FY25. For FY26, Consolidated Revenue from Operations stood at Rs 63,977 lakh, an increase of 14.43% compared to Rs 55,909 lakh in FY25. Consolidated Total Income for FY26 was Rs 65,667 lakh, up 13.27% from Rs 57,975 lakh in FY25. For FY26, the Consolidated Net Loss narrowed to Rs 716 lakh, compared to a Net Loss of Rs 872 lakh in FY25. Consolidated Total Comprehensive Loss for the year FY26 was Rs 174 lakh, a significant improvement from the loss of Rs 761 lakh in FY25. Standalone Financial Results: Standalone Revenue from Operations for Q4FY26 was Rs 11,112 lakh, recording a growth of 11.89% QoQ from Rs 9,931 lakh and 63.65% YoY from Rs 6,790 lakh in Q4FY25. Standalone Total Income for Q4FY26 stood at Rs 11,672 lakh, up 13.16% QoQ from Rs 10,315 lakh and 57.75% YoY from Rs 7,399 lakh in Q4FY25. The company reported a Standalone Net Loss of Rs 18 lakh for Q4FY26, narrowing significantly from a Net Loss of Rs 736 lakh in Q3FY26 and Rs 1,239 lakh in Q4FY25. For FY26, Standalone Revenue from Operations was Rs 41,349 lakh, an increase of 33.45% from Rs 30,985 lakh in FY25. Standalone Total Income for FY26 was Rs 43,149 lakh, showing a growth of 32.17% compared to Rs 32,647 lakh in FY25. Standalone Net Loss for FY26 stood at Rs 2,988 lakh, compared to a Net Loss of Rs 1,523 lakh in FY25. Business Highlights: Segment-wise Performance: Vaccines: The segment recorded revenue of Rs 10,795 lakh in Q4FY26 compared to Rs 6,790 lakh in Q4FY25. For FY26, revenue stood at Rs 41,025 lakh against Rs 30,984 lakh in FY25. Formulations: This segment reported revenue of Rs 5,880 lakh in Q4FY26 compared to Rs 6,463 lakh in Q4FY25. For FY26, revenue was Rs 22,952 lakh against Rs 24,925 lakh in FY25. Key Business Updates and Exceptional Items: During FY26, the Group recognized exceptional income of Rs 1,950 lakh in the consolidated statement of profit and loss. This includes Rs 857 lakh pursuant to a settlement agreement with Apotex Inc., USA, and Rs 1,092 lakh from the recognition of deferred consideration from the sale of domestic pharmaceutical brands of Panacea Biotec Pharma Limited (PBPL). The enrollment of study participants for the DengiAll Phase-III clinical trial has been completed. DengiAll is expected to be the first indigenous single-shot dengue vaccine in India, with an expected market entry by 2027. The company has received higher long-term business orders for vaccines from key institutional customers. The Board of Directors has recommended passing over the dividend on equity as well as preference shares for FY26 on account of losses during the year. The company is assessing the impact of the new Labour Codes (2020), which consolidate twenty-nine existing labour laws; incremental impacts have been accounted for based on available information. Result PDF

• Trendlyne
• 1 week 4 days ago

Biotechnology company Panacea Biotec announced Q3FY26 results Revenue: Rs 16,519 lakh against Rs 16,349 lakh during Q3FY25, change 1%. PBT: Rs 649 lakh against Rs 438 lakh during Q3FY25, change 48%. PAT: Rs 389 lakh against Rs 444 lakh during Q3FY25, change -12%. EPS: Rs 0.65 for Q3FY26. Result PDF

• Trendlyne
• 4 months ago